MedImmune Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Toby Zidle who wrote (130)	8/17/1998 2:26:00 PM
From: Cacaito	of 416

Cost is about $1000 per dose, full treatment is about 4 to 5 doses. This is from the Ross representative in the Brooklyn area. The product is intended for the premature babies less than 35 weeks of gestation. Compare the price to the costs of hospitalization due to bronchiolitis/pneumonia of about $5,000 to $50,000 an insurance has to pay for 4 to 5 days in the hospital, depending if the admission is to a regular ward or Peds Intensive care unit. The market for Synagis should be at least double the market for Respigam Respigam doses are given in one day hospitalization, or in one day visit special units for 6 to 8 hours of infusion IV. Synagis cut this need to cero, is a single shot in the office. Insurance are going to save money there too, no need to pay the one day hospitalization neither the one day stay special unit. Production of Synagis is more reliable than the plasma pool derived Respigam. Plasma pool costs just keep rising every year. Synagis is a recombinant product, much cheaper to produce. The facilities to produce it will be able to produce other monoclonal products in research or for commercialization.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next